logo
Pediatric Sleep Screener Boosts Diagnoses, Referrals

Pediatric Sleep Screener Boosts Diagnoses, Referrals

Medscape2 days ago
Children's poor sleep is associated with obesity, academic problems, suicide attempts, and other mental health concerns, but the issue is not consistently addressed in pediatric primary care. A new well-child-visit screening tool for primary care clinicians (PCCs) appears to help boost diagnosis and referrals, according to findings from a study published in JAMA Network Open .
Ariel A. Williamson, PhD, with The Ballmer Institute for Children's Behavioral Health, University of Oregon, Portland, Oregon, and colleagues tested an electronic, age-based sleep screener that evaluated infant bed sharing, snoring three nights a week, short sleep time, perceived sleep problems, and adolescent daytime sleepiness.
The researchers conducted a retrospective, observational case-control study in the Children's Hospital of Pennsylvania primary care network of 31 practices in Pennsylvania and New Jersey; 27 in suburban/rural settings and four in metropolitan settings.
During implementation, 204,872 patients completed the screening, with adoption in 89.5% of all well-child visits. The screening indicated that 9.7% of patients had frequent snoring, 12.2% had sleep problems, and 34.4% had insufficient sleep. Bed sharing was reported for 6.5% of infants and 14.7% of adolescents reported daytime sleepiness. The identification of sleep problems was followed by provision of family education resources.
Sleep Disorder Diagnosis 64% More Likely With Screener
Compared with the pre-implementation period, at well-child visits with a completed sleep screener, PCCs were significantly more likely to make a sleep disorder diagnosis (odds ratio [OR], 1.64; 95% CI, 1.56-1.73), order a polysomnogram (OR, 2.67; 95% CI, 2.32-3.20), and refer to sleep clinics (OR, 6.48; 95% CI, 5.03-8.34) or otolaryngology (OR, 4.46; 95% CI, 3.95-5.02).
Rupali Drewek, MD, a pediatric pulmonologist and co-medical director of the Sleep Medicine Program at Phoenix Children's in Phoenix, who was not involved with the study, told Medscape Medical News the screener is promising and its proactive approach — even in children with no obvious symptoms — allows for earlier intervention and improved quality of life.
'Sleep problems affect up to half of children at some point,' she said, 'yet they are rarely addressed unless parents bring them up. Implementing a standardized screening tool during routine pediatric visits ensures systematic identification of issues that might otherwise go unnoticed. Taking action early can lead to better health, better school performance, and less stress for families and the healthcare system.'
Adding a new screening tool should fit easily into a regular checkup without slowing workflow substantially, she said. 'It offers a scalable, low‑cost solution to reach millions of children.'
Educating the medical team will be important to successful implementation, she said.
'Everyone on the care team needs to know how to read the results and what to do next if a child's answers show there might be a sleep problem.'
Lessening Healthcare Inequities
In an accompanying editorial, Sarah M. Honaker, PhD, with the Department of Pediatrics at Indiana University School of Medicine, Indianapolis, and Stephen M. Downs, MD, MS, with the Department of Pediatrics, Wake Forest University in Winston Salem, North Carolina, said the screener, 'offers a refreshing departure from this pattern of asking PCCs to know more and do more. [T]his is an opportune time to study the implementation of systems that will support PCCs in providing evidence-based care.'
The editorialists wrote that the broad screening at well-child visits could help lessen healthcare inequities. They noted that children from minoritized backgrounds with a lower socioeconomic status are more likely, for instance, to have obstructive sleep apnea (OSA) and are less likely to receive timely, evidence-based care. 'For example, Black children are two to four times more likely to have OSA and less likely to receive a [polysomnogram] referral,' they wrote.
One of the main unanswered questions, Honaker and Downs wrote, is how much the educational components help once the problems have been identified and whether guidance about sleep duration results in actual improvements in sleep duration.
A key strength of the work is replicability in other health systems, with individual adaptations, the editorialists noted.
'[T]he system designed by Williamson and colleagues offers an excellent starting point for other healthcare systems seeking to support PCCs in prevention, identification, and management of pediatric sleep disruption,' they wrote.
Williamson reported receiving honoraria from the National Sleep Foundation, the American Academy of Pediatrics, and Wesleyan University and an honorarium and travel support from The Pennsylvania State University, outside the submitted work.
This study was supported by the Possibilities Project at Children's Hospital of Philadelphia and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Honaker reported receiving consulting fees from Covington LLC; grants from the National Heart, Lung, and Blood Institute; equity ownership of For Dreamers LLC; and grants from the American Academy of Sleep Medicine Foundation outside the submitted work. Downs reported that he is the co-creator of the Child Health Improvement through Computer Automation (CHICA) software and cofounder of Digital Health Solutions LLC, which licenses CHICA. Drewek reported no relevant financial relationships.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform

Yahoo

time9 minutes ago

  • Yahoo

BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform

Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Jim Cramer on UnitedHealth: 'It Could Come Back'
Jim Cramer on UnitedHealth: 'It Could Come Back'

Yahoo

time39 minutes ago

  • Yahoo

Jim Cramer on UnitedHealth: 'It Could Come Back'

UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer shed light on. Cramer showed a slight bit of optimism toward the company as he said: 'I think UnitedHealth's going to work here… I think it's going to work. I really do. Look, I'm not a believer. I don't like the fact that they had shenanigans, but I will say this: I think that the company is run by a very good CEO. It could come back.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, care delivery, and health management services. In addition, the company offers data analytics and technology-driven solutions for individuals, employers, governments, and health systems. During the August 7 episode, when a caller inquired about the company stock, Cramer responded: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)
Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

Yahoo

time39 minutes ago

  • Yahoo

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best stocks to invest in for beginners. Piper Sandler analyst Jessica Tassan reiterated a Buy rating on UnitedHealth Group Incorporated (NYSE:UNH) on August 5, setting a price target of $280.00. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) reported that its Q2 2025 revenue underwent a $12.8 billion year-over-year growth to $111.6 billion, attributed primarily to growth within Optum and UnitedHealthcare. Earnings from operations for the quarter were $5.2 billion, while adjusted net earnings were $4.08 per share. Management reported a full year 2025 revenue outlook in the $445.5 billion to $448.0 billion range, with a full year 2025 earnings outlook of at least $14.65 per share. UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store